In translating our understanding from preclinical studies, a pilot study performed in patients with breast cancer by our group using the TS inhibitor capecitabine demonstrated increased uptake in tumour lesions, compared to baseline, at 1 h after initiating treatment, demonstrating feasibility for the approach in humans [15]. Here, TYMS is linked to breast carcinoma.